

1 **Structural Variation Detection and Association Analysis of**
2 **Whole-Genome-Sequence Data from 16,905 Alzheimer’s Diseases Sequencing**
3 **Project Subjects**
4

5 Hui Wang^{1,2}, Beth A Dombroski^{1,2}, Po-Liang Cheng^{1,2}, Albert Tucci³, Ya-Qin Si³, John J Farrell⁴,
6 Jung-Ying Tzeng³, Yuk Yee Leung^{1,2}, John S Malamon⁵, The Alzheimer’s Disease Sequencing
7 Project, Li-San Wang^{1,2}, Badri N Vardarajan^{6,7}, Lindsay A Farrer^{4,8,9,10,11}, Gerard D Schellenberg^{1,2},
8 Wan-Ping Lee^{1,2}
9

10 ¹Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of
11 Pennsylvania, PA 19104, USA, ²Penn Neurodegeneration Genomics Center, Perelman School of
12 Medicine, University of Pennsylvania, PA 19104, USA, ³Bioinformatics Research Center, North
13 Carolina State University, NC 27695, USA, ⁴Department of Medicine (Biomedical Genetics), Boston
14 University School of Medicine, MA 02118, USA, ⁵Department of Surgery, Scholl of Medicine,
15 University of Colorado, CO 80045, USA, ⁶Taub Institute for Research on Alzheimer’s Disease and
16 the Aging Brain, College of Physicians and Surgeons, Columbia University, NY 10032, USA,
17 ⁷Department of Neurology, College of Physicians and Surgeons, Columbia University and the New
18 York Presbyterian Hospital, NY 10032, USA, ⁸Department of Neurology, Boston University School
19 of Medicine, MA 02118, USA, ⁹Department of Ophthalmology, Boston University School of
20 Medicine, MA 02118, USA, ¹⁰Department of Biostatistics, Boston University School of Public
21 Health, MA 02118, USA, ¹¹Department of Epidemiology, Boston University School of Public Health,
22 MA 02118, USA
23

24 **Search Terms:** Alzheimer's disease, Structural variation, Copy number variation

25 **Abstract**

26 Structural variations (SVs) are important contributors to the genetics of numerous human
27 diseases. However, their role in Alzheimer’s disease (AD) remains largely unstudied due to
28 challenges in accurately detecting SVs. Here, we analyzed whole-genome sequencing data from the
29 Alzheimer’s Disease Sequencing Project (ADSP, N=16,905 subjects) and identified 400,234
30 (168,223 high-quality) SVs. We found a significant burden of deletions and duplications in AD cases
31 (OR=1.05, $P=0.03$), particularly for singletons (OR=1.12, $P=0.0002$) and homozygous events
32 (OR=1.10, $P<0.0004$). On AD genes, the ultra-rare SVs, including protein-altering SVs in *ABCA7*,
33 *APP*, *PLCG2*, and *SORLI*, were associated with AD (SKAT-O $P=0.004$). Twenty-one SVs are in
34 linkage disequilibrium (LD) with known AD-risk variants, e.g., a deletion
35 (chr2:105731359-105736864) in complete LD ($R^2=0.99$) with rs143080277 (chr2:105749599) in
36 *NCK2*. We also identified 16 SVs associated with AD and 13 SVs associated with AD-related
37 pathological/cognitive endophenotypes. Our findings demonstrate the broad impact of SVs on AD
38 genetics.

39 Introduction

40 Alzheimer's disease (AD) is a neurodegenerative disease characterized by abnormal deposits of
41 extracellular A β plaques and intracellular neurofibrillary tangles¹. Typically, the accumulation of
42 these neuropathological changes is accompanied by neuronal death, leading to various symptoms
43 such as memory loss, apathy, difficulty swallowing, and walking². Among individuals aged 65 and
44 older, AD has an incidence rate of 10.7% and is the fifth-leading cause of death².

45 Genetic factors play a significant role in the etiology of AD, with the estimate of heritability
46 ranging from 58% to 79%³. However, genetic risk factors identified in previous studies explain only
47 a limited portion of heritability in AD. Mutations in *APP*, *PSEN1*, and *PSEN2* cause an early-onset
48 form of AD that is inherited as an autosomal dominant trait with high penetrance, but these mutations
49 only account for about 11% of early-onset AD that is approximately 0.6% of all AD⁴. *APOE*
50 genotype is the most prominent genetic risk factor for AD, and it is estimated that approximately
51 40-50% of individuals diagnosed with AD carry at least one copy of the *APOE* ϵ 4 risk allele⁵.
52 Overall, variations in *APP*, *PSEN1*, *PSEN2*, and *APOE* explain 20-50% of total genetic variance
53 (heritability) of AD, with *APOE* ϵ 4 accounting for most of this fraction due to its high frequency⁶.

54 In the past decade, genome-wide association studies (GWASs) identified > 75 additional AD risk
55 loci⁷⁻¹⁰. However, compared to *APOE* alleles, variants at those loci have a small effect size or are
56 rare in the population, contributing little to the overall heritability. *APOE* alleles alone can achieve an
57 AUC (Area Under the Receiver Operating Characteristic Curve) of 0.70 in predicting AD, whereas
58 the best AUC is only 0.61 when all other common single nucleotide variants (SNVs) are combined¹¹.
59 Even if all common SNVs, including *APOE* alleles, are considered, they only account for 24-33% of

60 phenotypic variance^{12,13}, which is much lower than the estimated heritability of AD and thus suggests
61 a role for other genetic mechanism.

62 Structural variants (SVs) are genomic alterations larger than 50bp that include deletions,
63 duplications, inversions, insertions, translocations, and complex combinations of these events. SVs
64 contribute more to individual genetic variation in terms of total nucleotide content, and thus the
65 difference in genomic sequences between two humans can increase from 0.1% with SNVs alone to
66 1.5% when SVs are considered¹⁴. Moreover, SVs can have profound effects on diseases and other
67 traits by disrupting gene function and regulation or modifying gene dosage through copy number
68 changes, deleting exons, and creating new splicing acceptors or donor sites. Therefore, analyzing
69 SVs has the potential to identify new genetic associations and account for the missing heritability in
70 AD.

71 SVs have been identified in several genes implicated in AD. For instance, duplications in *APP*
72 have been found to be the causal factor for autosomal dominant early-onset AD in a few families¹⁵⁻¹⁹.
73 In addition, a deletion in exon 9 of *PSENI* was identified in families with a form of early-onset AD
74 characterized by spastic paraparesis and atypical plaques^{20,21}. A low-copy repeat of 18 Kb in length
75 within *CRI*, which creates an additional C3b/C4b-binding site, may account for some GWAS signals
76 in the *CRI* region^{22,23}. The 1 Mb region on 17q21.31 containing *MAPT* has two major haplotypes H1
77 and H2, which are characterized by a ~900 Kb inversion flanked by a few duplication blocks and
78 tagged by a 238 bp deletion between exons 9 and 10 of *MAPT*²⁴. The H1 and H2 haplotypes are
79 associated with a range of neurodegenerative diseases including AD²⁴⁻²⁶. Additionally, copy number
80 variants (CNVs) in *AMY1*, which are correlated with salivary amylase protein level and digestion of

81 starchy food, are associated with AD. Individuals with high copy numbers (≥ 10) of *AMY1* have a
82 significantly lower risk of developing AD²⁷. These examples show that identification and analysis of
83 SVs in AD genetics hold great potential for uncovering new genetic associations and providing a
84 more comprehensive understanding of the genetic underpinnings of this complex disease.

85 To discover SV variants possibly contributing to AD risk, we evaluated SVs detected in
86 whole-genome sequence (WGS) data from 16,905 subjects from the Alzheimer's Disease
87 Sequencing Project (ADSP). We detected 400,234 SVs and found rare SVs in known AD genes,
88 including *SORL1*, *ABCA7* and *APP*, as well as SVs in linkage disequilibrium (LD) with AD GWAS
89 signals. Moreover, we found an increased burden of deletions and duplications (particularly,
90 singleton and homozygous events) in AD and identified possible risk SVs in *ADD3*, *ITPR2*, and
91 *NTM* through association analysis.

92 **Results**

93 SV discovery and characteristics

94 The SV discovery pipeline, including the Manta²⁸, Smoove²⁹, Svimmer³⁰, and GraphTyper2³⁰ SV
95 callers (**Methods**), was applied to ADSP³¹ R3 release (NG00067.v7) WGS data (N=16,905; **Table 1**).
96 We observed 400,234 SVs (231,385 deletions, 45,839 duplications, 119,648 insertions, and 3,362
97 inversions) of which 168,223 (98,805 deletions, 24,602 duplications, 44,130 insertions, and 506
98 inversions) were classified as high-quality calls (**Table S1, Methods**). Notably, genotype calls for
99 deletions exhibited superior quality with a lower missing genotype rate compared to duplications,
100 insertions, and inversions (**Fig. S1**). This observation highlights the higher quality of deletion
101 detection on WGS over other SV types using available callers.

102 On average, each individual had 14,607 (3,875 high-quality) deletions, 764 (288 high-quality)
103 duplications, 6,980 (2,504 high-quality) insertions, and 19 (3 high-quality) inversions. Individuals of
104 African ancestry had more SV calls compared to individuals of other ancestries (**Fig. 1A**), possibly
105 because the human reference genome is biased towards European ancestry or higher level of genetic
106 diversity in Africans³²⁻³⁴. Similar to SNVs, the first two principal components of common SVs
107 distinguished samples from different ancestral backgrounds (**Fig. 1B**). However, the third principal
108 component of SVs is associated with read length and sequencing platforms (**Fig. S2**), indicating
109 batch effect is an important confounding factor to consider when performing SV analysis.

110 Comparable to the allele frequency (AF) distribution of SNVs, most SVs are extremely rare.
111 Among 400,234 SVs, 94,923 (24%) are singletons, and 232,295 (58%) are rare with AF < 1% (**Fig.**

112 **S3**). When considering the 168,223 high-quality SVs, 67,595 (40%) are singletons, and 140,164
113 (83%) are rare with AF < 1%. **Fig. 1C** shows that the AF distribution of deletions is more similar to
114 the AF distribution of SNVs compared to other SV types. Analysis of the size of the SVs revealed
115 two peaks centered around 300 bp and 6,000 bp (**Fig. 1D**), suggesting the possibility that many SVs
116 are introduced by transposons, particularly, Alus (~300 bp) and L1s (~6,000 bp).

117 Functional annotation analysis performed using AnnotSV³⁵ showed that rare SVs are more likely
118 to be deleterious than common SVs (Wilcoxon Rank Sum $P < 0.0001$) (**Fig. 2A**). This finding was
119 confirmed using annotation from VEP³⁶, which shows that protein-altering SVs tend to be rare (odds
120 ratio [OR] = 4.71, Chi-Square $P < 0.0001$, **Fig. 2B**). Additionally, we observed a higher proportion of
121 singletons SVs in coding or regulatory regions (**Fig. 2C**), suggesting negative selection against
122 deleterious SVs in functionally important regions of the genome. Overall, our results highlight the
123 importance of evaluating rare SVs when studying genetic variation in human disease.

124 **Table 1. Characteristics of study participants (N = 16,905)**


	AD (N = 6,646)	Control (N = 6,938)	Unknown AD status (N = 3,321)
Age (SD)	74.62 (10.44)	77.40 (7.98)	72.04 (9.28)
Sex (%)			
Female	3,998 (60%)	4,639 (67%)	1,586 (48%)
Male	2,648 (40%)	2,299 (23%)	1,735 (52%)
APOE status^a (%)			
ε4	3,552 (54%)	2,188 (32%)	972 (30%)
No ε4	3,084 (46%)	4,661 (68%)	2,279 (70%)
Ancestry^b (%)			
European	4,381 (66%)	3,214 (46%)	2,871 (86%)
African American	1,454 (22%)	2,036 (29%)	129 (4%)
Latin American	769 (12%)	1,655 (24%)	253 (8%)
East Asian	18 (0.27%)	9 (0.13%)	32 (0.96%)
Other	24 (0.36%)	24 (0.35%)	36 (1%)
Ethnicity (%)			
non-Hispanic	5,523 (85%)	4,912 (71%)	1,058 (80%)
Hispanic	1,022 (15%)	2,003 (29%)	265 (20%)

125

126 AD, Alzheimer's disease; Age, age at onset for individuals with AD or age at last exam for non-AD
127 subjects; SD, standard deviation.

128 ^aAPOE ε4 status is based on rs429358 observed from whole genome sequencing data.

129 ^bAncestry is inferred using GRAF-pop³⁷.



130

131 **Fig. 1: Characteristics of high-quality SVs**

132 **A.** Number of high-quality SVs per individual by ancestry. **B.** Principal component analysis of
133 high-quality SV with MAF > 0.01 and Hardy-Weinberg Equilibrium (HWE) > 1e-5. **C.** The
134 cumulative fractions of variants by allele frequency. **D.** The size distribution of high-quality SVs.




Fig. 2: Functional annotation of SVs.

135
136
137
138
139
140

A. AnnotSV ranking scores of common ($AF \geq 0.01$) and rare ($AF < 0.01$) high-quality SVs. The rare SVs are more likely to be deleterious with higher AnnotSV ranking scores. **B.** VEP annotation of common ($AF \geq 0.01$) and rare ($AF < 0.01$) high-quality SVs. The protein-altering SVs tend to be rare. **C.** Percent of singletons in a specified functional category by VEP.

141 SV quality evaluation and laboratory validation

142 Evaluation of the sensitivity of SV calling pipeline using synthetic mutations³⁸ (**Methods**)
143 revealed a sensitivity of 99.4% for 4,000 deletions and 94.4% for 1,500 inversions (**Table S2**). We
144 did not perform an evaluation for insertions since the inserted sequences and positions are ambiguous
145 in the simulation of synthetic mutations.

146 Then, we evaluated our SV call set against external SV databases. Approximately 50% of the
147 high-quality SVs were detected in the Genome Aggregation Database (gnomAD, 292,307 SV sites),
148 but there was less overlap with SVs in the 1000 Genomes Project (1KG, 66,505 SV sites) (**Fig. S4**).
149 The difference was due to fewer samples in 1KG compared to gnomAD. The SV callset before
150 high-quality filtering had a higher recall (a higher percentage of SVs from gnomAD and 1KG) at the
151 cost of lower precision (a lower percentage of SVs confirmed by gnomAD and 1KG) (**Fig. S4, Fig.**
152 **S5**).

153 Of 95 SVs selected for experimental validation (**Table S3; Methods**), 78 were confirmed,
154 resulting in a sensitivity rate of 82%. When considering only high-quality SVs, the sensitivity
155 increased to 85% with 61 out of 72 SVs being experimentally validated. On individual genotype
156 level, an accuracy of 89% was achieved for 276 called genotypes for 95 SVs undergoing PCR
157 validation (**Table S4**), and this value increased to 92% for 207 called genotypes for 72 high-quality
158 SVs (**Table S4**).

159 SVs in linkage disequilibrium with known AD risk loci

160 SVs are larger genomic perturbations and may have more severe functional impact compared to

161 SNVs; therefore, SVs in LD with AD GWAS risk SNVs are more likely to account for the statistical
162 association in the regions, especially if the SNVs are not predicted to have an impact on protein
163 structure or gene expression. We identified 21 SVs (12 deletions, two duplications, and seven
164 insertions) that are in LD with established AD GWAS loci⁸⁻¹⁰ (**Table 2**). Three deletions, in particular,
165 showed high LD ($R^2 > 0.9$) with GWAS signals near or in *NCK2*, *NBEAL1*, and *TMEM106B*. A 5.5
166 Kb deletion (chr2:105731359-105736864) located 8 Kb upstream of *NCK2* is in perfect LD ($R^2 =$
167 0.99) with rs143080277 (chr2:105749599), which is a rare variant (AF = 0.005) in the intron of
168 *NCK2*¹⁰. A 5.2 Kb deletion (chr2:203034369-203039560) in *NBEAL1* intron and overlapping with
169 H3K27ac peak from Encode³⁹ is in high LD ($R^2 = 0.94$) with rs139643391 (chr2:202878716)¹⁰,
170 which is a 3 prime UTR variant of *WDR12*. A 323 bp (chr7:12242077-12242399) Alu deletion
171 located on the exon 8 of *TMEM106B* is in LD with *TMEM106B* intronic variants, rs5011436
172 (chr7:12229132, $R^2 = 0.92$)⁹ and rs13237518 (chr7:12229967, $R^2 = 0.90$)¹⁰, which are not only
173 associated with the risk of AD but also protect carriers of *C9ORF72* repeat expansion from the risk
174 of frontotemporal dementia⁴⁰.

175 Other deletions that are in moderate LD ($0.2 < R^2 < 0.9$) with GWAS signals can impact exons,
176 enhancers, transposons, and conserved regions (**Table 2**). A 446 bp deletion
177 (chr10:122457302-122457747) extending into exon 2 of *ARMS2* is in LD ($R^2 = 0.24$) with
178 rs7908662 (chr10:122413396, *PLEKHA1* intronic variant)¹⁰. A 310 bp deletion
179 (chr14:106774952-106775261) overlaps an enhancer element in the IGH gene cluster and is in LD
180 ($R^2 = 0.26$) with rs10131280 (chr14:106665591)¹⁰. A 310 bp Alu deletion
181 (chr12:113245316-113245625) in *TPCNI* intron is in LD ($R^2 = 0.73$) with rs6489896

182 (chr12:113281983)¹⁰. A 365 bp deletion (chr7:28174681-28175045) in *JAZF1* intron overlapping
183 evolutionally conserved sequence defined by phastCons and phyloP is in LD ($R^2 = 0.41$) with
184 rs1160871 (chr7:28129126)¹⁰.

185 The *MAPT* H1/H2 haplotype, defined by a 900 kb inversion and tagged by numerous SNVs, has
186 been associated with several neurodegenerative diseases, including progress supranuclear palsy,
187 frontotemporal disorders, Parkinson's disease, and AD^{24,25,41}. We identified five deletions and two
188 duplications in moderate LD ($R^2 = 0.35-0.67$, **Table 2**) with a H1/H2 tagging SNV (rs199515,
189 chr17:46779275), which is associated with AD¹⁰. These SVs further confirmed the complex genomic
190 structure in the region and highlight the difficulty in identifying the causal variants within the H1/H2
191 haplotype. **Table 2** also describes seven high-quality insertions, excluding those in problematic
192 regions (**Methods**), that are in LD with AD GWAS signals.

Table 2. High-confident SVs in linkage disequilibrium with AD GWAS signals

SNV	Chr	Pos	Original P	SV	BETA	P ^a	R ²	Gene
rs115186657	2	105618971	1.30E-08 ^b	chr2:105731359-105736864:DEL*	0.0652	0.1	0.6	NCK2
rs143080277	2	105749599	2.10E-13 ^c				5	
rs139643391	2	202878716	1.10E-08 ^c	chr2:203034369-203039560:DEL	0.0137	0.1	0.9	WDR12
rs5011436	7	12229132	2.70E-09 ^b	chr7:12242077-12242399:DEL	0.0020	0.7	0.9	TMEM106B
rs13237518	7	12229967	4.90E-11 ^c				2	
rs1160871	7	28129126	9.80E-09 ^c	chr7:28174681-28175045:DEL	0.0119	0.0	0.4	JAZF1
rs7908662	10	122413396	2.60E-09 ^c	chr10:122457302-122457747:DEL	-0.0047	0.5	0.2	PLEKHA1
rs6489896	12	113281983	1.80E-09 ^c	chr12:113245316-113245625:DEL	0.0055	0.5	0.7	TPCN1
rs10131280	14	106665591	4.30E-10 ^c	chr14:106774952-106775261:DEL	-0.0076	0.4	0.2	IGH
rs199515	17	46779275	9.30E-13 ^c	chr17:46009357-46009595:DEL	-0.0146	0.0	0.6	WNT3/MAPT
				chr17:46099028-46099351:DEL	-0.0171	0.0	0.6	WNT3/MAPT

				chr17:46146541-46146855:DEL	-0.0162	0.0 4	0.6 2	WNT3/MAPT
				chr17:46205463-46208952:DUP	-0.0129	0.3 1	0.3 5	WNT3/MAPT
				chr17:46237501-46238225:DEL	-0.0061	0.4 8	0.5 4	WNT3/MAPT
				chr17:46277789-46282210:DEL	-0.0185	0.0 7	0.5 9	WNT3/MAPT
				chr17:46135409-46292152:DUP	-0.0037	0.5 4	0.4 2	WNT3/MAPT
rs10947943	6	41036354	1.10E-09 ^c	chr6:40959079-40959079:INS	-0.0106	0.1 9	0.2 3	UNC5CL
rs3740688	11	47358789	5.40E-13 ^d , 8.78E-9 ^b	chr11:47775210-47775210:INS	-0.0049	0.5 9	0.2 8	SPI1
rs6489896	12	113281983	1.80E-09 ^c	chr12:113286417-113286417:INS	0.0094	0.4 2	0.6 9	TPCN1
rs7146179	14	52832135	6.99E-11 ^b	chr14:52832930-52832930:INS	0.0043	0.6 5	0.8 0	FERMT2
rs28394864	17	49373413	4.90E-10 ^b	chr17:49320942-49320942:INS	-0.0204	0.0 5	0.4 1	ABI3
rs138190086	17	63460787	7.50E-09 ^d	chr17:63204093-63204093:INS	0.0036	0.8 0	0.2 3	ACE
rs2154482	21	26148613	7.66E-10 ^b	chr21:26136136-26136136:INS	0.0156	0.1 8	0.4 0	APP

194

195 ^aP values from association analysis by fastGWA⁴².

196 ^bWightman *et al.*, 2021.

197 ^cBellenguez *et al.*, 2022.

198 ^dKungle *et al.*, 2019.

199 *SVs that have been experimentally validated.

200 SVs on AD risk/protective genes

201 We first focused on SVs that were reported to be associated with AD in previous studies⁴³⁻⁴⁷. Ten
202 rare SVs (**Table S5**) were replicated in our SV callset. A 417 Kb duplication (**Fig. S6**) covering the
203 *APP* is identified in one individual with early onset of AD at his age of 52. Subsequently, we noticed
204 two other carriers of duplication who were dropped from the initial analysis due to failed quality
205 control. One individual having the duplication was his sibling and developed AD at age of 49, and
206 the other individual is his sibling's offspring who developed AD at age of 53. This finding provides
207 compelling evidence that the duplication of *APP* is a rare cause of autosomal dominant early-onset
208 AD^{15-17,19}. A 7.68 Mb inversion covering the entire 21q21.2 is identified in one individual with early
209 onset of AD at her age of 60 years old. The inversion was experimentally validated, and the
210 alignments showed clear breakpoints of the inversion (**Fig. S7**). In addition, the 5.6 Kb deletion,
211 covering exons 2-5 of *HLA-DRA* found in nine AD cases by Swaminathan *et al.*⁴³, are present in
212 eight samples in our analysis, including five AD cases (three showed early onset of AD with age < 65)
213 and three unclear-AD-status individuals (two are diagnosed as progressive supranuclear palsy, and
214 the remaining one is with BRAAK stage 2). A few other SVs, encompassing *GBE1*, *EPHA5*, and
215 *EVC*, are replicated in our dataset.

216 SVs on AD risk/protective genes could interfere with protein function and lead to disease.
217 Therefore, we identified 77 high-confident SVs (**Methods**), including 44 deletions, 15 duplications,
218 and 18 insertions on AD risk/protective genes determined by the ADSP gene verification committee
219 (see Table2 on <https://adsp.niagads.org/gvc-top-hits-list/>). Nine deletions and five duplications have

220 an allele count ≥ 5 (AF ranging from 0.0002 to 0.4690), but none of them were significantly
221 associated with AD (**Table S6**), and none of these SVs were tagged known AD-associated SNVs.
222 The remaining 35 deletions and 10 duplications are ultra-rare (MAC < 5), of which 34 (25 deletions
223 and 9 duplications) are singletons (**Table 3**). We performed an aggregated analysis of 45 ultra-rare
224 CNVs (35 deletions and 10 duplications), using SKAT-O test⁴⁸ instead of calculating individual
225 p-values given the limited statistical power due to low allele count, and observed a significant
226 association with AD status ($P = 0.0050$), highlighting the contribution of ultra-rare CNVs to the
227 etiology of AD.

228 Notably, 14 of the 35 ultra-rare deletions and 8 of the 10 ultra-rare duplications are protein
229 altering variants. For instance, we identified in *SORL1* a 192 Kb duplication spanning exons 1-5 and
230 an 8 Kb deletion affecting exon 6 (**Fig. 4**). Previous studies indicated that *SORL1* deficiency can lead
231 to AD through defects in the endolysosome-autophagy network^{49,50}, and nearly all individuals with
232 damaging SNVs in *SORL1* developed AD⁵¹. Eight out of nine individuals with *ABCA7* exonic
233 deletions or duplications in our data (**Fig. S8**) developed AD, supporting previous studies that
234 observed loss-of-function *ABCA7* variants among AD cases⁵². We also found protein-altering
235 ultra-rare deletions and duplications in *APP*, *PLCG2*, *PILRA*, *CASP7*, *MS4A6A*, *RIN3*, *APOE*, and
236 *PSENI* (**Table 3**). In particular, 17 of 21 individuals with ultra-rare deletions in *PLCG2* were AD
237 cases (SKAT-O $P = 0.029$). We also identified 18 high-quality insertions located in AD genes (**Table**
238 **S7**). However, the aggregated effect of these insertions on AD risk was not significant (SKAT-O $P =$
239 0.21).

Table 3. Ultra-rare SVs on AD genes

SV	Size	AC (Case) [AgeOnset,Sex,Eth]	AC (Control) [Age,Sex,Eth]	Gene	Type	Protein-altering ^a
chr19:1050368-1050973 ^b	605	4 [74, F, AA] [69, M, AA] [81, F, AA] [81, F, AA]	0	ABCA7	DEL	Yes
chr16:81775821-81829769 ^b	53,948	4 [75, M, E] [56, F, E] [-, M, E] [-, M, E]	0	PLCG2	DEL	Yes
chr19:1052156-1060559	8,403	3 [72, F, AA] ^d [72, F, AA]	1 [70, F, L]	ABCA7	DUP	Yes
chr16:81860089-81940500	80,411	3 [89, F, E] [56, F, E] [-, F, E]	0	PLCG2	DEL	Yes
chr2:127094683-127094740 ^b	57	2 [86, M, E] [87, F, E]	1 [84, F, E]	BIN1	DEL	No
chr7:100296733-100385675	88,942	2 [85, F, E] [56, F, E]	0	PILRA	DEL	Yes
chr16:81907252-81907401	149	2 [67, F, E] [61, F, E]	0	PLCG2	DEL	No
chr14:92611452-92611515	63	2 [90, M, E] [61, F, E]	0	RIN3	DEL	No

chr19:1043504-1053484	9,980	1 [78, M, E]	0	ABCA7	DEL	Yes
chr19:1054326-1061615 ^b	7,289	1 [67, M, E]	0	ABCA7	DUP	Yes
chr15:58720431-58721649	1,218	1 [79, F, AA]	0	ADAM10	DEL	No
chr21:25815144-26232105 ^e	416,961	1 [52, M, E]	0	APP	DUP	Yes
chr21:25958556-25971275	12,719	1 [-, F, E]	0	APP	DEL	No
chr21:26163874-26163976	102	1 [70, M, E]	0	APP	DUP	No
chr2:127102503-127104954	2,451	1 [70, M, AA]	0	BIN1	DEL	No
chr10:113725274-11372628 8	1,014	1 [75, F, E]	0	CASP7	DEL	Yes
chr11:60138757-60178011	39,254	1 [65, F, AA]	1 [82, F, E]	MS4A6A	DEL	Yes
chr11:60179765-60450406 ^b	270,641	1 [-, F, O]	0	MS4A6A	DUP	Yes
chr11:86050643-86054032	3,389	1 [70, F, AA]	0	PICALM	DEL	No
chr16:81734058-81749307^c	15,249	1 [-, F, E]	0	PLCG2	DEL	Yes
chr16:81749081-81749132	51	1 [75, M, AA]	0	PLCG2	DEL	No
chr16:81755550-81764402^c	8,852	1 [84, F, E]	0	PLCG2	DEL	Yes
chr16:81772599-81777744	5,145	1 [69, F, E]	0	PLCG2	DEL	Yes
chr16:81792449-81792587	138	1 [68, F, E]	0	PLCG2	DEL	No
chr16:81798030-81802305 ^b	4,275	1 [72, M, E]	1 [89, F, AA]	PLCG2	DEL	Yes
chr16:81822810-81822862 ^b	52	1 [83, M, E]	0	PLCG2	DEL	No
chr16:81868226-81868350	124	1 [66, F, AA]	1 [70, M, AA]	PLCG2	DEL	No
chr14:92369331-92644481	275,150	1 [85, M, AA]	0	RIN3	DUP	Yes
chr14:92531510-92573409	41,899	1 [-, F, E]	0	RIN3	DUP	Yes
chr11:121303351-12149566 9	192,318	1 [61, F, AA]	0	SORL1	DUP	Yes
chr11:121490959-12149941 3	8,454	1 [70, F, E]	0	SORL1	DEL	Yes
chr19:1051380-1051420	40	0	1 [81, M, AA]	ABCA7	DEL	No
chr15:58621731-58622007	276	0	1 [64, F, L]	ADAM10	DUP	No
chr19:44909364-44909819	455	0	1 [80, M, AA]	APOE	DUP	Yes
chr21:26013065-26013159	94	0	1 [69, F, AA]	APP	DEL	No

chr2:127064222-127064288	66	0	1 [89, F, AA]	BIN1	DEL	No
chr2:127092466-127092526	60	0	1 [68, M, L]	BIN1	DEL	No
chr2:127094016-127102983	8,967	0	1 [80, F, E]	BIN1	DEL	No
chr1:207604022-207605343	1,321	0	1 [-, F, L]	CR1	DEL	No
chr7:100377717-100378235	518	0	1 [64, M, AA]	PILRA	DEL	No
chr16:81746327-81746435 ^b	108	0	1 [85, F, E]	PLCG2	DEL	No
chr16:81885235-81893072	7,837	0	1 [73, F, AA]	PLCG2	DEL	Yes
chr14:73215181-73313643	98,462	0	1 [84, F, E]	PSEN1	DEL	Yes
chr14:92535796-92535871 ^b	75	0	1 [85, F, E]	RIN3	DEL	No
chr14:92605335-92607867 ^b	2,532	0	1 [77, F, E]	RIN3	DEL	No

241 ^aSV overlaps with gene exons.


242 ^bSVs that are experimentally validated.

243 ^cSVs with read depth and split reads support but no PCR product for flanking primers.

244 ^dRepresents homozygous even

245 ^eTwo additional family individuals had the duplication but failed quality control due to less confident genotypes. Nevertheless, alignment evidence strongly
246 supports the presence of duplication. Their onset ages are 49 and 53.

247 F, female; M, male; E, European, A, Asian; AA, African American; L, Latin American; O, other; “-“ represents missing age. AD risk/protective genes are
248 selected by ADSP Gene Verification Committee (<https://adsp.niagads.org/gvc-top-hits-list/>).



249

250 **Fig. 4: Ultra-rare deletion and duplication on *SORL1*.**

251 **A.** Deletion and duplication on *SORL1*. **B.** The 192 Kb duplication covers part of *SORL1* and
252 *SC5D*. **C.** The 8.45 Kb deletion covers exon 6 of *SORL1*.

253 SV burden in AD

254 We performed burden tests of SVs, including CNVs (deletions and duplications), insertions, and
255 inversions separately and collectively, and found a moderate burden of CNVs in AD cases (OR =
256 1.05, $P = 0.0321$), but no significant burden of insertions and inversions was detected (**Table S8**).

257 The increased CNV burden in AD cases was driven by the presence of singletons (OR = 1.12, $P =$

258 0.0002) and homozygous CNVs (OR = 1.10, $P = 0.0004$). This is consistent with the burden of
259 ultra-rare CNVs in AD genes, in which 34 out of 45 ultra-rare CNVs are singletons. The result
260 suggests that singletons and homozygous CNVs, which were not considered in previous association
261 analyses, may be important contributors to the genetic basis of AD.

262 SVs associated with AD and AD endophenotypes

263 From our association analysis using 12,908 subjects (6,328 AD cases and 6,580 controls,
264 excluding subjects with unknown AD diagnosis and SV quality outliers, **Methods**), six common and
265 nine rare SVs were found associated with AD at a false discovery rate (FDR) < 0.2 (**Table 4, Fig.**
266 **5A**). Notably, a 12.7 Kb (chr10:110025269-110037941, AF = 0.000426) deletion in the intron of
267 *ADD3* was exclusively found in 11 AD cases and not in any control. In gnomAD, this deletion has a
268 lower AF of 0.000277, which may be attributed to fewer AD cases in gnomAD. Moreover, there is a
269 rare SNV (rs773892439) in complete LD ($R^2 = 1$) with this deletion. Since the SNV is extremely rare
270 (gnomAD AF of 0.00022, TOPMed⁵³ AF of 0.00033, and our AF of 0.00065), it was not included in
271 previous GWASs. Another rare deletion (chr12:26731939-26732033, AF = 0.00155) in *ITPR2* was
272 found in 33 AD cases and 7 controls. The deletion is in intron 2 of *ITPR2*, which may be a regulatory
273 region as indicated by the H3K4me1 and H3K27ac signals as well as transcription factor ChIP-seq
274 clusters in this region (**Fig. S11A**). *ITPR2* was found to be widely expressed across different brain
275 regions (**Fig. S11B**), with a higher expression in AD (**Fig. S11C**). SVs in *LMNTD1*, *LHFPL6*,
276 *RNA5SP293*, *RABGAP1*, *ADD3*, *ITPR2*, and *CLIC4* were confirmed by PCR validation.

277 Under a nominal $P < 0.05$, there are 2,411 high-quality SVs not in the problematic regions

278 **(Methods)**. Enrichment analysis of the 2,411 SVs revealed an over-representation of neuronal
279 function-related terms, such as axon development and synaptic membrane (**Fig. 5B**). Among the
280 2,411 SVs, 37 are protein-altering variants (**Table S9**), including protein-altering variants in genes
281 that have been found to be related to AD, e.g., *NTN3* and *CIB2*^{54,55}.

282 Since a significant homozygous CNV burden is detected, we performed association using a
283 recessive model, of which assumes that two copies of the alternative allele are required to alter the
284 risk. As a result, a 1 Kb deletion (chr11:131726334-131727274) in the intron of *NTM* is the only SV
285 with FDR < 0.2 using the recessive model. Interestingly, the variants inside *NTM* have been
286 associated with tau pathology in previous studies^{56,57}.

287 In addition, we extended our association analysis to endophenotypes. **Table 5** shows six
288 common and six rare SVs with an FDR < 0.2 for cognitive functions, CSF biomarkers, and
289 neuropathologic measurements. No significant genomic inflation was observed for all
290 endophenotypes (**Fig. S12**), indicating that confounding factors are well adjusted. The most
291 significant signal is a rare deletion (chr4:188173309-188183202, AF = 0.0028, $P = 1.72 \times 10^{-08}$)
292 located in the intergenic region that is a transcription factor binding site. A rare SNV (rs1418703978)
293 which shows even lower AF (gnomAD AF of 0.00019, TOPMed AF of 0.00026, and our AF of
294 0.00047) is in complete LD with the deletion. A 100 Kb deletion (chr6:31391686-31488609)
295 encompassing the entire *MICA* gene is associated with amyloid presence ($P = 1.09 \times 10^{-07}$). Previous
296 studies showed that the *MICA* deletion is accompanied by a *MICB* null allele (MICB0107N)⁵⁸,
297 indicating loss of function of both *MICA* and *MICB*. These genes are located in the MHC locus,
298 which has been found associated with AD risk⁵⁹.

Table 4. Association analysis of AD status (FDR < 0.2)

SV	Size	AF	BETA	SE	P	FDR	Type	SYMBOL
Common SVs								
chr4:176948164-176948480	316	0.6387	0.02	0.01	1.83E-04	0.15	DEL	AC097518.2
chr16:22983114-22983114	-	0.0296	0.07	0.02	2.06E-04	0.16	INS	AC127459.2
chr21:32026205-32026205	-	0.2962	-0.03	0.01	2.13E-04	0.16	INS	HUNK
chr12:25590144-25591138 ^a	994	0.0424	-0.05	0.01	2.16E-04	0.16	DUP	LMNTD1
chr2:8476683-8476971	288	0.9347	-0.04	0.01	2.41E-04	0.18	DEL	LINC00299
chr13:39375608-39375802	194	0.0291	0.06	0.02	2.83E-04	0.19	DEL	LHFPL6 ^a
Rare SVs								
chr9:107896000-107900424 ^a	4,424	0.0037	0.18	0.05	7.81E-05	0.10	DEL	RNA5SP293
chr6:113757605-113757605	-	0.0083	-0.13	0.03	9.75E-05	0.11	INS	FO393415.2
chr9:122989084-122989182 ^a	98	0.0062	-0.15	0.04	1.09E-04	0.12	DUP	RABGAP1
chr7:102726253-102733877	7,624	0.0072	-0.14	0.04	1.65E-04	0.15	DEL	AC105052.5
chr10:110025269-110037941 ^a	12,672	0.0004	0.51	0.14	2.81E-04	0.19	DEL	ADD3
chr14:70979489-70979489	-	0.0182	-0.09	0.02	2.87E-04	0.19	INS	PCNX1
chr9:117738391-117742456	4,065	0.0002	-0.69	0.19	2.98E-04	0.19	DEL	AL160272.2
chr12:26731939-26732033 ^a	94	0.0016	0.27	0.07	3.05E-04	0.19	DEL	ITPR2
chr1:236250828-236252511	1,683	0.0005	0.49	0.14	3.07E-04	0.19	DEL	ERO1B
chr1:24852253-24857535 ^a	5,282	0.0096	0.11	0.03	3.26E-04	0.20	DEL	CLIC4
Recessive model								
chr11:131726334-131727274	940	0.0009 ^b	0.27	0.07	1.17E-04	0.12	DEL	NTM

300


301 ^aSVs that are experimentally validated.

302 ^bHomozygous allele frequency.

303 AF, allele frequency; FDR, false discovery rate; SE, standard error; DEL, deletion; DUP, duplication; INS, insertion.

304

305



306

307

Fig. 5: Association of SVs with AD and enrichment analysis.

308

A. Association of SVs with AD. Red line represents an FDR of 0.05. Gray line represents an

309

FDR of 0.2. **B.** Enrichment analysis for high-quality SVs (nominal $P < 0.05$) that are not in

310

problematic regions. BP, Biological Process; CC, Cellular Component; MF, Molecular Function;

311

KEGG, Kyoto Encyclopedia of Genes and Genomes.

312

Table 5. Association analysis of AD endophenotypes (FDR < 0.2)

Phenotype	SV	Size	AF	BETA	SE	P	FDR	Type	SYMBOL
Common SVs									
EXF	chr11:22412330-22412446	116	0.1800	-0.10	0.02	2.93E-06	0.014	DEL	SLC17A6
MEM	chr8:1096443-1097561	1,118	0.0480	-0.24	0.05	7.43E-06	0.041	DEL	DLGAP2
LAN	chr17:46810995-46811289	294	0.0968	0.15	0.03	2.02E-05	0.121	DEL	WNT3
EXF	chr1:4228390-4228390	-	0.1090	-0.11	0.03	8.23E-05	0.136	INS	EEF1DP6
MEM	chr5:119121855-119122904	1,049	0.0416	-0.25	0.06	3.79E-05	0.140	DEL	DMXL1
MEM	chr5:34754523-34754523	-	0.0986	-0.14	0.03	4.99E-05	0.179	INS	RAI14
Rare SVs									
REAG	chr4:188173309-188183202	9,893	0.0028	-2.23	0.40	1.72E-08	0.001	DEL	LINC02434
AMY	chr6:31391686-31488609	96,923	0.0017	-0.61	0.12	1.09E-07	0.010	DEL	MICA
EXF	chr9:85662873-85662873	-	0.0051	-0.58	0.12	3.57E-06	0.014	INS	AGTPBP1
EXF	chr18:48162022-48162075	53	0.0006	-1.44	0.36	6.96E-05	0.119	DUP	ZBTB7C
AMY	chr9:117738391-117742456	4,065	0.0011	-0.66	0.15	6.39E-06	0.181	DEL	AL160272.2
LAN	chr3:33035060-33035060	-	0.0027	-0.74	0.18	4.46E-05	0.195	INS	GLB1

314 AF, allele frequency; FDR, false discovery rate; SE, standard error; DEL, deletion; DUP, duplication; INS, insertion; REAG, NIA-Reagan
315 diagnosis of AD; AMY, amyloid presence (dichotomous); EXF, executive function score; MEM, memory score; LAN, language score.

316 Discussion

317 The complexity of generating high-quality SVs on WGS for SV association analysis is
318 challenging, and a major concern is to ensure the analysis is not based on false positive SVs. To
319 achieve this, we developed a pipeline to filter SVs and employed stringent criteria during the burden
320 analysis to only include high-quality SVs. For each significant SV, we examined read coverages and
321 other alignment signals by Samplot and performed experimental validations if samples are available
322 in the lab (**Methods**). Despite our efforts, false positive/negative calls on individual samples can still
323 occur, which may undermine the result of the analysis. Therefore, we suggest a broader validation of
324 significant SVs using long reads as the cost and accuracy of long reads improve rapidly.

325 We reported SVs in LD with known AD risk loci (such as SNVs in *NCK2*, *WDR12*, and
326 *TMEM106B*) and on AD risk/protective genes (such as *APP*, *SORLI*, and *ABCA7*). Other than that,
327 researchers can use our SV calling set to explore SVs on a particular gene of interest. For example,
328 there are SVs on genes that might be related to the risk of disease by interacting with well-known AD
329 genes (such as *PSEN2* and *APOE*). A deletion (chr1:226827423-226834076, near *PSEN2*) spanning
330 the entire *lnc-PSEN2-7* and overlapping with a possible enhancer supported by H3K27ac signals
331 (**Fig. S9**) was identified in an individual (Latin American ancestry, inferred by GRAF-pop³⁷), who
332 had onset of AD symptoms at age 71 years old. We also observed in one AD case an exonic deletion
333 in *MPO* (**Fig. S10**), a gene that has been reported to affect AD risk through interact with *APOE*⁶⁰.

334 Our association analysis yielded some interesting findings. One notable discovery is a 12 Kb
335 deletion in *ADD3*, which is a gene encoding a subunit of adducin protein called γ -adducin and was
336 reported associated with neural function. The α -adducin encoded by *ADD1* can either dimerize with

337 β -adducin (*ADD2*) or γ -adducin (*ADD3*) to form the adducin protein⁶¹. Heterodimers of α -adducin
338 and β -adducin are mainly in red blood cells and neurons as the expression of adducin β were
339 tissue-specific and α -adducin and γ -adducin were present in most tissue types⁶¹. Adducin plays an
340 essential role in the membrane cytoskeleton of red blood cells⁶² and is highly expressed in dendritic
341 spines⁶³ and growth cones of neurons⁶⁴. Moreover, overexpression of γ -adducin promotes
342 neurite-like process in COS7 cells⁶⁵, suggesting important roles of adducin in brain function.
343 Variants in *ADD3* were found to be associated with hypertension, cerebral palsy, renal disease,
344 vascular disease and cognitive dysfunction^{66,67}. Along with tau and a few other CDK5 substrates,
345 γ -adducin is also hyperphosphorylated (possibly by CDK5) in APP/PS1 mice⁶⁸. Interestingly, *ADD3*
346 displayed a significantly lower expression in 6-month-old APP/PS1 mice while significantly higher
347 expression in 14-month-old APP/PS1 mice⁶⁹. In addition, γ -adducin is involved in
348 trans-Golgi-network through re-organization of the actin network around the Golgi complex⁶⁵,
349 therefore, may be able to regulate intracellular trafficking of APP and relevant secretases.

350 Our study provided a valuable resource for the analysis of SVs in AD. We identified SVs from
351 WGS data across a large cohort of AD participants with diverse ancestry. We reported SVs tagging
352 AD risk SNVs, providing new mechanism of actions for GWAS signals. Deleterious rare SVs on
353 well-known AD genes have been discovered. We found a higher burden of ultra-rare SVs on AD
354 genes, and overall, higher burden of homozygous and singleton CNVs in AD patients. Finally, our
355 association analysis revealed a few potential candidate SVs and genes that are worthy of further
356 study.

357 **Methods**

358 Study subjects

359 Alzheimer's Disease Sequencing Project (ADSP)³¹ is a collaborative project aiming at
360 identifying new variants, genes, and therapeutic targets in AD. In the R3 release of ADSP, 16,905
361 subjects were collected across 24 cohorts and whole genome sequencing was performed by Illumina
362 HiSeqX, HiSeq2000, HiSeq2500, and NovaSeq platforms. The ancestry of each individual was
363 inferred using GRAF-pop³⁷. The samples came from diverse ancestries with 10,466 Europeans,
364 3,619 African Americans, 2,677 Latin Americans, 59 East Asians, 84 of other ancestries. There are
365 6,646 AD cases, 6,938 controls and 3,321 subjects with unknown status in this study. Sample
366 characteristics were displayed in **Table 1**.

367 After removing duplicates and subjects without AD diagnosis, 13,371 samples were kept for
368 analysis. Then, 463 outlier subjects, with too many ($> \text{median} + 4 * \text{MAD}$) SV calls or too few ($<$
369 $\text{median} - 4 * \text{MAD}$) high-quality SV calls, were removed (**Fig. S13**). There were 12,908 samples
370 (6,328 cases and 6,580 controls) remaining for association analysis (**Fig. S14**). Compared to the
371 samples that were kept for further analysis, outliers are more likely to be of smaller insert size and
372 lower coverage (**Fig. S15**).

373 SV calling

374 **Fig. S16** illustrates the SV calling pipeline. For each sample, SVs were called by Manta²⁸
375 (v1.6.0) and Smoove²⁹ (v0.2.5) with default parameters. Calls from Manta and Smoove were merged
376 by Svimmer³⁰ to generate a union of two call sets for a sample. Unresolved non-reference 'breakends'

377 (BNDs) and SVs > 10 Mb were filtered. Then, all individual sample VCF files were merged together
378 by Svimmer as input to GraphTyper2 (v2.7.3)³⁰ for joint genotyping. SV calls after joint-genotyping
379 are comparable across the samples, therefore, can be used directly in genome-wide association
380 analysis³⁰. The pipeline is available on <https://github.com/whtop/SV-ADSP-Pipeline>.

381 SV selection by algorithmic models

382 GraphTyper2 annotates each SV call by algorithmic models, i.e., breakpoint, coverage, and
383 aggregated models³⁰. Note that an SV call can be annotated by multiple models so there will be
384 duplicated records in VCF if an SV call has more than one algorithmic model. Aggregated model has
385 the highest recall than the other two models³⁰. Therefore, SVs were selected based on the order of
386 aggregated, breakpoint, and then coverage models (**Table S1**).

387 High-quality SVs

388 A subset of SV calls was defined as high-quality calls. The criteria for high-quality SVs can be
389 found in GraphTyper2 study³⁰: For deletion, QD ($QUAL$ divided by non-reference sequence depth) >
390 12 & ($ABHet$ (allele balance for heterozygous calls (read count of call2/(call1 + call2)) where the
391 called genotype is call1/call2, -1 if no heterozygous calls.) > 0.30 | $ABHet < 0$) & ($AC /$
392 NUM_MERGED_SVS (number of SVs merged)) < 25 & $PASS_AC$ (number of alternate alleles in
393 called genotyped that have “FT” field as “PASS”) > 0 & $PASS_ratio$ (ratio of genotype calls that
394 have “FT” field as “PASS”) > 0.1; For duplication, $QD > 5$ & $PASS_AC > 0$ & ($AC /$
395 NUM_MERGED_SVS) < 25; For insertion, $PASS_AC > 0$ & (AC / NUM_MERGED_SVS) < 25
396 & $PASS_ratio > 0.1$ & ($ABHet > 0.25$ | $ABHet < 0$) & $MaxAAS$ (maximum alternative allele

397 support per alternative allele) > 4; For inversions: $PASS_AC > 0 \ \& \ (\ AC \ / \ NUM_MERGED_SVS \)$
398 $< 25 \ \& \ PASS_ratio > 0.1 \ \& \ (\ ABHet > 0.25 \ | \ ABHet < 0 \) \ \& \ MaxAAS > 4$. Then, if an SV still has
399 multiple records in VCF due to multiple algorithmic models, we selected based on the order of
400 aggregated, breakpoint, and then coverage models.

401 Problematic regions

402 There are regions in the human genome that tend to have anomalous, or high signal in WGS
403 experiments⁷⁰. SVs that reside in those regions can be unreliable and should be reported. Specifically,
404 we compiled problematic regions in the genome from the following sources: (1) the ENCODE
405 blacklist: a comprehensive set of regions that could result in erroneous signal⁷¹; (2) the 1000 Genome
406 masks: regions of the genome that are more or less accessible to next generation sequencing methods
407 using short reads; (3) the set of assembly gaps defined by UCSC; (4) the set of segmental
408 duplications defined by UCUC; (5) the low-complexity regions, satellite sequences and simple
409 repeats defined by RepeatMasker (Tarailo-Graovac and Chen 2009).

410 High-confident SVs

411 For any SVs reported on AD risk/protective genes and from association, Samplot⁷³ was used to
412 check their alignment supports of read depth and/or split reads if SV types are deletions, duplications,
413 and inversions. For insertions, which cannot be inspected using Samplot, we kept insertions that are
414 high-quality and not in the problematic regions.

415 SV annotation

416 SVs were annotated using VEP (V 107)³⁶ and annotSV (V 3.1.1)³⁵. SVs that were annotated (by
417 VEP) to be able to cause transcript ablation/amplification, stop gain, start/stop lost, frameshift,
418 inframe deletion/insertion, missense mutation, and affecting splice acceptor/donor were classified as
419 protein-altering variants. The impact of SVs is also evaluated by annotSV ranking score, which is an
420 adaptation of the work provided by the joint consensus recommendation of the American College of
421 Medical Genetics and Genomics (ACMG) and ClinGen⁷⁴.

422 SV validation

423 Structural variants from the 1000 Genomes Project phase III⁷⁵ and gnomAD⁷⁶ were downloaded
424 from dbVar database⁷⁷ with study accession ID estd219 and nstd166. On chromosomes 1-22, there
425 are 66,505 and 292,307 SVs from the 1000 Genomes Project and gnomAD, respectively. For
426 deletions/duplications/inversions, calls with at least 50% reciprocal overlapping were considered as
427 replicated. For insertions, we searched for calls with breakpoints within 500bp. Then, we estimated
428 sensitivity of GraphTyper2 by synthetic mutations (i.e., “spiking-in” SVs) generated from three
429 samples by Malamon *et al.*³⁸.

430 For PCR validation, the sequence surrounding the variants was extracted and used to design
431 PCR primers. For deletions under 1,100 bp, primers were designed outside of the breakpoints to
432 amplify across the deletion sequence. For deletions where the reference allele was too large to be
433 amplified by PCR, a double PCR approach was used. For the first PCR, one primer was designed
434 within the putative deletion sequence while the other primer was placed external to the deletion
435 breakpoint. PCR amplification using these primers would yield a product from the reference allele.

436 For the second PCR, both primers flanked the putative deletion. Only samples that contained the
437 deletion, would yield a product for this second PCR.

438 For duplication variants, since most duplications occur in a head to tail orientation, PCR primers
439 were designed to amplify a product in this orientation. A forward direction primer was designed at
440 the 3' end of the duplicated sequence and a reverse primer was designed at the 5' end of the
441 duplicated sequence. These primers would amplify a product across the boundary at the duplication
442 site. All PCR primer sequences were submitted to the Blast-like alignment tool (BLAT)⁷⁸ to check
443 for uniqueness of the sequence. When available, samples from three individuals reported as
444 heterozygous for the variant were used for sequence validation along with one control (or reference)
445 sample. When possible, samples from multiple families were used for validation.

446 Genomic DNA (~50ng) was amplified using a SimpliAmp Thermal Cycler (Applied Biosystems)
447 in a 20ul reaction volume with HotStarTaq Master Mix (Qiagen) in the presence of 2uM primers
448 (IDT). The PCR conditions used were: 95°C 15min followed by 30 cycles of 95°C 20sec, 55°C
449 30sec, 72°C 2min with a final extension of 72°C 7min. The amplified PCR products were prepared
450 for Sanger sequencing by adding ExoSAP-IT (USB) and incubating at 37°C for 45min followed by
451 80°C for 15min. The PCR products were then Sanger sequenced using the BigDye® Terminator v3.1
452 Cycle Sequencing kit (Part No. 4336917 Applied Biosystems). The sequencing reaction contained
453 BigDye® Terminator v3.1 Ready Reaction Mix, 5X Sequencing Buffer, 5M Betaine solution (Part
454 No. B0300 Sigma) and 0.64uM sequencing primer (IDT) in a total volume of 5ul. The sequencing
455 reaction was performed in a SimpliAmp Thermal Cycler (Applied Biosystems) using the following
456 program: 96°C 1min followed by 25 cycles of 96°C 10sec, 50°C 5sec, 60°C 1min15sec. The

457 products were cleaned using XTerminator and SAM Solution (Applied Biosystems) with 30min of
458 shaking at 1800rpm followed by centrifugation at 1000 rpm for 2min. The sequencing products were
459 analyzed on a SeqStudio Genetic Analyzer (Applied Biosystems) and the sequencing traces were
460 analyzed using Sequencher 5.4 (Gene Code)

461 SVs on AD risk loci and AD genes

462 We first searched for SVs that are in linkage disequilibrium (LD) with AD associated loci from
463 three GWASs⁸⁻¹⁰. There are 123 unique variants that reached genome-wide significance from three
464 studies. After excluding nine variants that were not found in the WGS data, we searched for SVs that
465 are in LD ($R^2 > 0.2$) with the rest of 114 variants. For SVs, P value from fastGWA⁴² adjusting for
466 PCs 1-5, age, sex, sequencing centers, sequencing platforms, and PCR status were also provided.

467 Then, we investigated SVs on known AD genes. A list of 20 expert curated AD risk/protective
468 causal genes were downloaded from: <https://adsp.niagads.org/index.php/gvc-top-hits-list>. These
469 genes were identified by a review of literature, pathway analysis, and by integration of genetic
470 studies with myeloid genomics. All deletions, duplications, and inversions with missing rate less than
471 0.5 that overlap with these genes were inspected. Association of ultra-rare SVs on 20 AD genes were
472 evaluated using SKAT-O test from R package SKAT⁴⁸.

473 Overall SV burden in AD

474 Overall SV burden between AD cases and controls was compared. SV burden was measured by
475 the difference in the number of high-quality SVs in cases and controls. Logistic regression model
476 adjusted for covariates (PCs 1-5, age, sex, sequencing center, sequencing platform, PCR status) were

477 used. One-sided empirical p values (assuming increased SV burden in cases) were calculated based
478 on 10,000 permutations. Particularly, we evaluated the burden of singletons and homozygous SVs in
479 AD compared to controls.

480 Association and functional analyses

481 In total, 136,092 SVs with a missing rate < 0.5 and minor allele count > 5 were evaluated using
482 mixed linear model based tool (fastGWA) implemented in GCTA⁴². Age, sex, sample PCR status,
483 sequencing platforms, sequencing centers, and PCs 1-5 calculated from common SNVs were
484 included as covariates. The age of cases was determined by the age at disease onset. The age of
485 controls was determined by the age at the last exam. Sparse genetic relationship matrix was
486 generated using SNVs as well with a cutoff of 0.05. High-confident deletions, duplications, and
487 inversions were selected by Samplot and experimentally validated by PCR. For insertions, only
488 high-confident ones that are high-quality and not on the problematic regions were reported.
489 Enrichment analysis for nominal significant signals (2,411 high-quality SVs with $P < 0.05$) was
490 performed using clusterProfiler⁷⁹.

491 Other than binary AD diagnosis, we also assessed SV association with cognitive scores, fluid
492 biomarkers, and neuropathological measurements that were harmonized by the ADSP Phenotype
493 Harmonization Consortium⁸⁰. Cognitive scores include memory score (N = 6,413), executive
494 function score (N = 5,762), language score (N = 6,130), and visuospatial score (N = 1,126)⁸⁰. Fluid
495 biomarkers include CSF Amyloid beta (N = 1,110), tau (N = 1,086), and P-tau (N = 1,087).
496 Neuropathological measurements include Thal amyloid phases (N = 543), CERAD amyloid scores

497 (N = 2,361), amyloid presence (dichotomous, N = 2,361), BRAAK tau phases (N = 2,357), ADNC
498 severity scores (N = 540), NIA-REAGAN criteria for AD (N = 1,060).

499 **Declarations**

500 Ethics approval and consent to participate

501 Consent for publication

502 Not applicable.

503 Availability of data and materials

504 <https://github.com/whtop/SV-ADSP-Pipeline>

505 <https://dss.niagads.org/>

506 Competing interests

507 The authors declare that they have no competing interests.

508 Funding

509 HW and PLC report grant support from RF1-AG074328 and P30-AG072979. AT, YQS, and JYT

510 report grant support from RF1-AG074328. YYL reports grant support from U54-AG052427 and

511 U24-AG041689. LSW reports grant support from U24-AG041689, U54-AG052427,

512 U01-AG032984, U01-AG058654, and P30AG072979. LAF reports grant support from

513 U54-AG052427, U01-AG058654, U01-AG062602, R01-AG048927, and P30-AG072978. WPL

514 reports grant support from RF1-AG074328, P30-AG072979, U54-AG052427, and U24-AG041689.

515 Acknowledgements

516 *The ADGC cohorts*

517 The ADGC cohorts include Adult Changes in Thought (ACT) (U01 AG006781, U19 AG066567),
518 the Alzheimer's Disease Research Centers (ADRC) (P30 AG062429, P30 AG066468, P30
519 AG062421, P30 AG066509, P30 AG066514, P30 AG066530, P30 AG066507, P30 AG066444, P30
520 AG066518, P30 AG066512, P30 AG066462, P30 AG072979, P30 AG072972, P30 AG072976, P30
521 AG072975, P30 AG072978, P30 AG072977, P30 AG066519, P30 AG062677, P30 AG079280, P30
522 AG062422, P30 AG066511, P30 AG072946, P30 AG062715, P30 AG072973, P30 AG066506, P30
523 AG066508, P30 AG066515, P30 AG072947, P30 AG072931, P30 AG066546, P20 AG068024, P20
524 AG068053, P20 AG068077, P20 AG068082, P30 AG072958, P30 AG072959), the Chicago Health
525 and Aging Project (CHAP) (R01 AG11101, RC4 AG039085, K23 AG030944), Indiana Memory and
526 Aging Study (IMAS) (R01 AG019771), Indianapolis Ibadan (R01 AG009956, P30 AG010133), the
527 Memory and Aging Project (MAP) (R01 AG17917), Mayo Clinic (MAYO) (R01 AG032990, U01
528 AG046139, R01 NS080820, RF1 AG051504, P50 AG016574), Mayo Parkinson's Disease controls
529 (NS039764, NS071674, 5RC2HG005605), University of Miami (R01 AG027944, R01 AG028786,
530 R01 AG019085, IIRG09133827, A2011048), the Multi-Institutional Research in Alzheimer's Genetic
531 Epidemiology Study (MIRAGE) (R01 AG09029, R01 AG025259), the National Centralized
532 Repository for Alzheimer's Disease and Related Dementias (NCRAD) (U24 AG021886), the
533 National Institute on Aging Late Onset Alzheimer's Disease Family Study (NIA- LOAD) (U24
534 AG056270), the Religious Orders Study (ROS) (P30 AG10161, R01 AG15819), the Texas
535 Alzheimer's Research and Care Consortium (TARCC) (funded by the Darrell K Royal Texas
536 Alzheimer's Initiative), Vanderbilt University/Case Western Reserve University (VAN/CWRU) (R01
537 AG019757, R01 AG021547, R01 AG027944, R01 AG028786, P01 NS026630, and Alzheimer's

538 Association), the Washington Heights-Inwood Columbia Aging Project (WHICAP) (RF1
539 AG054023), the University of Washington Families (VA Research Merit Grant, NIA: P50AG005136,
540 R01AG041797, NINDS: R01NS069719), the Columbia University Hispanic Estudio Familiar de
541 Influenza Genetica de Alzheimer (EFIGA) (RF1 AG015473), the University of Toronto (UT
542 (funded by Wellcome Trust, Medical Research Council, Canadian Institutes of Health Research), and
543 Genetic Differences (GD) (R01 AG007584). The CHARGE cohorts are supported in part by
544 National Heart, Lung, and Blood Institute (NHLBI) infrastructure grant HL105756 (Psaty),
545 RC2HL102419 (Boerwinkle) and the neurology working group is supported by the National Institute
546 on Aging (NIA) R01 grant AG033193.

547 *The CHARGE cohorts*

548 The CHARGE cohorts participating in the ADSP include the following: Austrian Stroke
549 Prevention Study (ASPS), ASPS-Family study, and the Prospective Dementia Registry-Austria
550 (ASPS/PRODEM-Aus), the Atherosclerosis Risk in Communities (ARIC) Study, the Cardiovascular
551 Health Study (CHS), the Erasmus Rucphen Family Study (ERF), the Framingham Heart Study
552 (FHS), and the Rotterdam Study (RS). ASPS is funded by the Austrian Science Fond (FWF) grant
553 number P20545-P05 and P13180 and the Medical University of Graz. The ASPS-Fam is funded by
554 the Austrian Science Fund (FWF) project I904), the EU Joint Programme – Neurodegenerative
555 Disease Research (JPND) in frame of the BRIDGET project (Austria, Ministry of Science) and the
556 Medical University of Graz and the Steiermärkische Krankenanstalten Gesellschaft.
557 PRODEM-Austria is supported by the Austrian Research Promotion agency (FFG) (Project No.
558 827462) and by the Austrian National Bank (Anniversary Fund, project 15435. ARIC research is

559 carried out as a collaborative study supported by NHLBI contracts (HHSN268201100005C,
560 HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,
561 HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). Neurocognitive data
562 in ARIC is collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902,
563 2U01HL096917 from the NIH (NHLBI, NINDS, NIA and NIDCD), and with previous brain MRI
564 examinations funded by R01-HL70825 from the NHLBI. CHS research was supported by contracts
565 HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080,
566 N01HC85081, N01HC85082, N01HC85083, N01HC85086, and grants U01HL080295 and
567 U01HL130114 from the NHLBI with additional contribution from the National Institute of
568 Neurological Disorders and Stroke (NINDS). Additional support was provided by R01AG023629,
569 R01AG15928, and R01AG20098 from the NIA. FHS research is supported by NHLBI contracts
570 N01-HC-25195 and HHSN268201500001I. This study was also supported by additional grants from
571 the NIA (R01s AG054076, AG049607 and AG033040 and NINDS (R01 NS017950). The ERF study
572 as a part of EUROSPAN (European Special Populations Research Network) was supported by
573 European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received
574 funding from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant
575 agreement HEALTH-F4- 2007-201413 by the European Commission under the programme "Quality
576 of Life and Management of the Living Resources" of 5th Framework Programme (no.
577 QLG2-CT-2002- 01254). High-throughput analysis of the ERF data was supported by a joint grant
578 from the Netherlands Organization for Scientific Research and the Russian Foundation for Basic
579 Research (NWO-RFBR 047.017.043). The Rotterdam Study is funded by Erasmus Medical Center

580 and Erasmus University, Rotterdam, the Netherlands Organization for Health Research and
581 Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of
582 Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European
583 Commission (DG XII), and the municipality of Rotterdam. Genetic data sets are also supported by
584 the Netherlands Organization of Scientific Research NWO Investments (175.010.2005.011,
585 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the
586 Research Institute for Diseases in the Elderly (014-93-015; RIDE2), and the Netherlands Genomics
587 Initiative (NGI)/Netherlands Organization for Scientific Research (NWO) Netherlands Consortium
588 for Healthy Aging (NCHA), project 050-060-810. All studies are grateful to their participants, faculty
589 and staff. The content of these manuscripts is solely the responsibility of the authors and does not
590 necessarily represent the official views of the National Institutes of Health or the U.S. Department of
591 Health and Human Services.

592 Authors' contribution

593 HW, YYL, JF, JSM, LSW, BNV, LAF, GDS, and WPL performed variant detection, quality
594 check, and genotype/phenotype acquisition. HW, AT, YQS, JYT, and WPL performed statistical
595 analyses. BAD, PLC, and GDS performed experimental validation. HW, BAD, PLC, AT, YQS, JF,
596 JYT, YYL, JSM, BNV, LAF, GDS, and WPL interpreted results. HW and WPL wrote the first draft
597 of the manuscript. All authors read, critically revised, and approved the manuscript.

598 References

- 599 1. Jack Jr, C. R. *et al.* NIA-AA research framework: toward a biological definition of Alzheimer's
600 disease. *Alzheimers Dement.* **14**, 535–562 (2018).
- 601 2. Gaugler, J. *et al.* 2022 Alzheimer's disease facts and figures. *ALZHEIMERS Dement.* **18**,
602 700–789 (2022).
- 603 3. Gatz, M. *et al.* Role of genes and environments for explaining Alzheimer disease. *Arch. Gen.*
604 *Psychiatry* **63**, 168–174 (2006).
- 605 4. Mendez, M. F. Early-onset Alzheimer Disease and Its Variants. *Contin. Minneap. Minn* **25**,
606 34–51 (2019).
- 607 5. Farrer, L. A. *et al.* Effects of age, sex, and ethnicity on the association between apolipoprotein E
608 genotype and Alzheimer disease: a meta-analysis. *Jama* **278**, 1349–1356 (1997).
- 609 6. Selkoe, D. J. & Podlisny, M. B. Deciphering the genetic basis of Alzheimer's disease. *Annu. Rev.*
610 *Genomics Hum. Genet.* **3**, 67–99 (2002).
- 611 7. Lambert, J.-C. *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for
612 Alzheimer's disease. *Nat. Genet.* **45**, 1452–1458 (2013).
- 613 8. Kunkle, B. W. *et al.* Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk
614 loci and implicates A β , tau, immunity and lipid processing. *Nat. Genet.* **51**, 414–430 (2019).
- 615 9. Wightman, D. P. *et al.* A genome-wide association study with 1,126,563 individuals identifies
616 new risk loci for Alzheimer's disease. *Nat. Genet.* **53**, 1276–1282 (2021).
- 617 10. Bellenguez, C. *et al.* New insights into the genetic etiology of Alzheimer's disease and related
618 dementias. *Nat. Genet.* **54**, 412–436 (2022).
- 619 11. Leonenko, G. *et al.* Genetic risk for alzheimer disease is distinct from genetic risk for amyloid
620 deposition. *Ann. Neurol.* **86**, 427–435 (2019).
- 621 12. Ridge, P. G., Mukherjee, S., Crane, P. K., Kauwe, J. S. K. & Consortium, A. D. G. Alzheimer's
622 disease: analyzing the missing heritability. *PLOS ONE* **8**, e79771 (2013).
- 623 13. Lee, S. H. *et al.* Estimation and partitioning of polygenic variation captured by common SNPs
624 for Alzheimer's disease, multiple sclerosis and endometriosis. *Hum. Mol. Genet.* **22**, 832–841
625 (2013).
- 626 14. Pang, A. W. *et al.* Towards a comprehensive structural variation map of an individual human
627 genome. *Genome Biol.* **11**, 1–14 (2010).
- 628 15. Rovelet-Lecrux, A. *et al.* APP locus duplication causes autosomal dominant early-onset
629 Alzheimer disease with cerebral amyloid angiopathy. *Nat. Genet.* **38**, 24–26 (2006).
- 630 16. Sleegers, K. *et al.* APP duplication is sufficient to cause early onset Alzheimer's dementia with
631 cerebral amyloid angiopathy. *Brain* **129**, 2977–2983 (2006).
- 632 17. Blom, E. S. *et al.* Low prevalence of APP duplications in Swedish and Finnish patients with
633 early-onset Alzheimer's disease. *Eur. J. Hum. Genet.* **16**, 171–175 (2008).
- 634 18. Kasuga, K. *et al.* Identification of independent APP locus duplication in Japanese patients with
635 early-onset Alzheimer disease. *J. Neurol. Neurosurg. Psychiatry* **80**, 1050–1052 (2009).
- 636 19. Hooli, B. V. *et al.* Role of common and rare APP DNA sequence variants in Alzheimer disease.
637 *Neurology* **78**, 1250–1257 (2012).
- 638 20. Crook, R. *et al.* A variant of Alzheimer's disease with spastic paraparesis and unusual plaques

- 639 due to deletion of exon 9 of presenilin 1. *Nat. Med.* **4**, 452–455 (1998).
- 640 21. Smith, M. J. *et al.* Variable phenotype of Alzheimer’s disease with spastic paraparesis. *Ann.*
641 *Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc.* **49**, 125–129 (2001).
- 642 22. Brouwers, N. *et al.* Alzheimer risk associated with a copy number variation in the complement
643 receptor 1 increasing C3b/C4b binding sites. *Mol. Psychiatry* **17**, 223–233 (2012).
- 644 23. Kucukkilic, E. *et al.* Complement receptor 1 gene (CR1) intragenic duplication and risk of
645 Alzheimer’s disease. *Hum. Genet.* **137**, 305–314 (2018).
- 646 24. Baker, M. *et al.* Association of an extended haplotype in the tau gene with progressive
647 supranuclear palsy. *Hum. Mol. Genet.* **8**, 711–715 (1999).
- 648 25. Allen, M. *et al.* Association of MAPT haplotypes with Alzheimer’s disease risk and MAPT brain
649 gene expression levels. *Alzheimers Res. Ther.* **6**, 1–14 (2014).
- 650 26. Wang, H., Wang, L.-S., Schellenberg, G. & Lee, W.-P. The role of structural variations in
651 Alzheimer’s disease and other neurodegenerative diseases. *Front. Aging Neurosci.* (2023).
- 652 27. Byman, E. *et al.* Alpha-amylase 1A copy number variants and the association with memory
653 performance and Alzheimer’s dementia. *Alzheimers Res. Ther.* **12**, 1–10 (2020).
- 654 28. Chen, X. *et al.* Manta: rapid detection of structural variants and indels for germline and cancer
655 sequencing applications. *Bioinformatics* **32**, 1220–1222 (2016).
- 656 29. Layer, R. M., Chiang, C., Quinlan, A. R. & Hall, I. M. LUMPY: a probabilistic framework for
657 structural variant discovery. *Genome Biol.* **15**, 1–19 (2014).
- 658 30. Eggertsson, H. P. *et al.* GraphTyper2 enables population-scale genotyping of structural variation
659 using pangenome graphs. *Nat. Commun.* **10**, 1–8 (2019).
- 660 31. Beecham, G. W. *et al.* The Alzheimer’s Disease Sequencing Project: study design and sample
661 selection. *Neurol. Genet.* **3**, (2017).
- 662 32. Campbell, M. C. & Tishkoff, S. A. African genetic diversity: implications for human
663 demographic history, modern human origins, and complex disease mapping. *Annu Rev Genomics*
664 *Hum Genet* **9**, 403–433 (2008).
- 665 33. Gomez, F., Hirbo, J. & Tishkoff, S. A. Genetic variation and adaptation in Africa: implications
666 for human evolution and disease. *Cold Spring Harb. Perspect. Biol.* **6**, a008524 (2014).
- 667 34. Consortium, G. P., Auton, A. & Brooks, L. D. A global reference for human genetic variation.
668 *Nature* **526**, 68–74 (2015).
- 669 35. Geoffroy, V. *et al.* AnnotSV: an integrated tool for structural variations annotation.
670 *Bioinformatics* **34**, 3572–3574 (2018).
- 671 36. McLaren, W. *et al.* The ensembl variant effect predictor. *Genome Biol.* **17**, 1–14 (2016).
- 672 37. Jin, Y., Schaffer, A. A., Feolo, M., Holmes, J. B. & Kattman, B. L. GRAF-pop: a fast
673 distance-based method to infer subject ancestry from multiple genotype datasets without
674 principal components analysis. *G3 Bethesda Md* **9**, 2447–2461 (2019).
- 675 38. Malamon, J. S. *et al.* A comparative study of structural variant calling strategies using the
676 Alzheimer’s Disease Sequencing Project’s whole genome family data. *bioRxiv* 2022–05 (2022).
- 677 39. Consortium, E. P. An integrated encyclopedia of DNA elements in the human genome. *Nature*
678 **489**, 57 (2012).
- 679 40. Van Blitterswijk, M. *et al.* TMEM106B protects C9ORF72 expansion carriers against
680 frontotemporal dementia. *Acta Neuropathol. (Berl.)* **127**, 397–406 (2014).

- 681 41. Zabetian, C. P. *et al.* Association analysis of MAPT H1 haplotype and subhaplotypes in
682 Parkinson's disease. *Ann. Neurol.* **62**, 137–144 (2007).
- 683 42. Jiang, L. *et al.* A resource-efficient tool for mixed model association analysis of large-scale data.
684 *Nat. Genet.* **51**, 1749–1755 (2019).
- 685 43. Swaminathan, S. *et al.* Analysis of copy number variation in Alzheimer's disease: the
686 NIALOAD/NCRAD Family Study. *Curr. Alzheimer Res.* **9**, 801–814 (2012).
- 687 44. Hooli, B. V. *et al.* Rare autosomal copy number variations in early-onset familial Alzheimer's
688 disease. *Mol. Psychiatry* **19**, 676–681 (2014).
- 689 45. Rovelet-Lecrux, A. *et al.* A genome-wide study reveals rare CNVs exclusive to extreme
690 phenotypes of Alzheimer disease. *Eur. J. Hum. Genet.* **20**, 613–617 (2012).
- 691 46. Chapman, J. *et al.* A genome-wide study shows a limited contribution of rare copy number
692 variants to Alzheimer's disease risk. *Hum. Mol. Genet.* **22**, 816–824 (2013).
- 693 47. Lladó, A. *et al.* Large APP locus duplication in a sporadic case of cerebral haemorrhage.
694 *Neurogenetics* **15**, 145–149 (2014).
- 695 48. Wu, M. C. *et al.* Rare-variant association testing for sequencing data with the sequence kernel
696 association test. *Am. J. Hum. Genet.* **89**, 82–93 (2011).
- 697 49. Dykxhoorn, D. M. *et al.* Characterization of an Alzheimer disease-associated deletion in SORL1.
698 *Alzheimers Dement.* **17**, e055472 (2021).
- 699 50. Hung, C. *et al.* SORL1 deficiency in human excitatory neurons causes APP-dependent defects in
700 the endolysosome-autophagy network. *Cell Rep.* **35**, 109259 (2021).
- 701 51. Holstege, H. *et al.* Characterization of pathogenic SORL1 genetic variants for association with
702 Alzheimer's disease: a clinical interpretation strategy. *Eur. J. Hum. Genet.* **25**, 973–981 (2017).
- 703 52. Steinberg, S. *et al.* Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. *Nat.*
704 *Genet.* **47**, 445–447 (2015).
- 705 53. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.
706 *Nature* **590**, 290–299 (2021).
- 707 54. Sethna, S. *et al.* CIB2 regulates mTORC1 signaling and is essential for autophagy and visual
708 function. *Nat. Commun.* **12**, 3906 (2021).
- 709 55. Bai, B. *et al.* Proteomic landscape of Alzheimer's disease: novel insights into pathogenesis and
710 biomarker discovery. *Mol. Neurodegener.* **16**, 55 (2021).
- 711 56. White, C. C. *et al.* A genome-wide investigation of clinicopathologic endophenotypes uncovers a
712 new susceptibility locus for tau pathology at Neurotrimin (NTM). *Alzheimers Dement.* **17**,
713 e051682 (2021).
- 714 57. Wang, H. *et al.* Genome-wide interaction analysis of pathological hallmarks in Alzheimer's
715 disease. *Neurobiol. Aging* **93**, 61–68 (2020).
- 716 58. Ota, M. *et al.* On the MICA deleted-MICB null, HLA-B* 4801 haplotype. *Tissue Antigens Brief*
717 *Commun.* **56**, 268–271 (2000).
- 718 59. Zalocusky, K. A. *et al.* Neuronal ApoE upregulates MHC-I expression to drive selective
719 neurodegeneration in Alzheimer's disease. *Nat. Neurosci.* **24**, 786–798 (2021).
- 720 60. Reynolds, W. F. *et al.* MPO and APOEε4 polymorphisms interact to increase risk for AD in
721 Finnish males. *Neurology* **55**, 1284–1290 (2000).
- 722 61. Li, X. & Bennett, V. Adducin: structure, function and regulation. *Cell. Mol. Life Sci. CMLS* **57**,

- 723 884–895 (2000).
- 724 62. Mische, S. M., Mooseker, M. S. & Morrow, J. S. Erythrocyte adducin: a calmodulin-regulated
725 actin-bundling protein that stimulates spectrin-actin binding. *J. Cell Biol.* **105**, 2837–2845
726 (1987).
- 727 63. Bennett, V., Gardner, K. & Steiner, J. P. Brain adducin: a protein kinase C substrate that may
728 mediate site-directed assembly at the spectrin-actin junction. *J. Biol. Chem.* **263**, 5860–5869
729 (1988).
- 730 64. Kiang, K. M.-Y. & Leung, G. K.-K. A review on adducin from functional to pathological
731 mechanisms: future direction in cancer. *BioMed Res. Int.* **2018**, (2018).
- 732 65. Lou, H., Park, J. J., Phillips, A. & Loh, Y. P. γ -Adducin promotes process outgrowth and
733 secretory protein exit from the Golgi apparatus. *J. Mol. Neurosci.* **49**, 1–10 (2013).
- 734 66. Gonzalez-Fernandez, E. *et al.* The adducin saga: pleiotropic genomic targets for precision
735 medicine in human hypertension—vascular, renal, and cognitive diseases. *Physiol. Genomics* **54**,
736 58–70 (2022).
- 737 67. Krueger, M. C. *et al.* Mutations in gamma adducin are associated with inherited cerebral palsy. *Ann.*
738 *Neurol.* **74**, 805–814 (2013).
- 739 68. Wu, H.-Y. *et al.* β -Amyloid induces pathology-related patterns of tau hyperphosphorylation at
740 synaptic terminals. *J. Neuropathol. Exp. Neurol.* **77**, 814–826 (2018).
- 741 69. Liang, J.-W. *et al.* Application of weighted gene co-expression network analysis to explore the
742 key genes in Alzheimer’s disease. *J. Alzheimers Dis.* **65**, 1353–1364 (2018).
- 743 70. Scherer, S. W. *et al.* Challenges and standards in integrating surveys of structural variation. *Nat.*
744 *Genet.* **39**, S7–S15 (2007).
- 745 71. Amemiya, H. M., Kundaje, A. & Boyle, A. P. The ENCODE blacklist: identification of
746 problematic regions of the genome. *Sci. Rep.* **9**, 1–5 (2019).
- 747 72. Tarailo-Graovac, M. & Chen, N. Using RepeatMasker to identify repetitive elements in genomic
748 sequences. *Curr. Protoc. Bioinforma.* **Chapter 4**, 4.10.1–4.10.14 (2009).
- 749 73. Belyeu, J. R. *et al.* Samplot: a platform for structural variant visual validation and automated
750 filtering. *Genome Biol.* **22**, 1–13 (2021).
- 751 74. Riggs, E. R. *et al.* Technical standards for the interpretation and reporting of constitutional
752 copy-number variants: a joint consensus recommendation of the American College of Medical
753 Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). (2020).
- 754 75. Sudmant, P. H. *et al.* An integrated map of structural variation in 2,504 human genomes. *Nature*
755 **526**, 75–81 (2015).
- 756 76. Collins, R. L. *et al.* A structural variation reference for medical and population genetics. *Nature*
757 **581**, 444–451 (2020).
- 758 77. Lappalainen, I. *et al.* DbVar and DGVA: public archives for genomic structural variation. *Nucleic*
759 *Acids Res.* **41**, D936–D941 (2012).
- 760 78. Kent, W. J. BLAT—the BLAST-like alignment tool. *Genome Res.* **12**, 656–664 (2002).
- 761 79. Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R package for comparing biological
762 themes among gene clusters. *Omics J. Integr. Biol.* **16**, 284–287 (2012).
- 763 80. Mukherjee, S. *et al.* Cognitive domain harmonization and cocalibration in studies of older adults.
764 *Neuropsychology* (2022).

765